Imricor Secures FDA Clearance for NorthStar MRI Mapping System for US Market
Imricor Medical Systems is a pioneering medical technology company specializing in developing innovative MRI-compatible products for cardiac ablation procedures. Founded in 2006, the company has established itself as the first and only provider of commercially viable and safe imaging catheter (iCMR) products designed to be used during magnetic resonance imaging (MRI) scans.
The company’s core product lineup includes the Vision-MR Ablation Catheter 2.0, Vision-MR Diagnostic Catheter, Advantage-MR EP Recorder/Stimulator, and the NorthStar Mapping System. These groundbreaking medical devices enable physicians to perform cardiac ablation procedures directly inside an MRI, offering unprecedented real-time imaging and precision for treating heart rhythm disorders. By integrating MRI technology with interventional cardiology, Imricor is transforming how complex cardiac procedures are performed.
Publicly traded on the Australian Securities Exchange (ASX:IMR), Imricor is committed to advancing electrophysiology by providing cutting-edge medical technology that enhances patient outcomes and surgical capabilities. The company has a global presence and continues to drive innovation in MRI-guided medical interventions, with a focus on developing safe, effective, and technologically advanced solutions for cardiac medical professionals.
© 2026 StockWire X Pty Ltd. All rights reserved.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.